Latest Medical Mergers & Acquisitions in the U.S. 🏥💼

Bristol-Myers Squibb & Mirati Therapeutics 🤝💊 Details: Bristol-Myers Squibb, headquartered in the United States, is acquiring Mirati Therapeutics, also based in the U.S., in a deal valued at approximately $4.8 billion. This acquisition aims to enhance Bristol-Myers Squibb’s oncology portfolio with Mirati’s advanced cancer therapies. Mirati, known for its innovative treatments targeting specific cancer mutations, complements Bristol-Myers Squibb's existing pipeline, focusing on precision medicine in oncology. Eli Lilly & DICE Therapeutics 💉🔬 Details: Eli Lilly, a global pharmaceutical company based in the U.S., has acquired DICE Therapeutics, a biotechnology firm also located in the U.S., for around $2.4 billion. DICE Therapeutics specializes in developing therapies for autoimmune and inflammatory diseases. This acquisition is set to strengthen Eli Lilly’s research and development capabilities in these areas, enhancing its pipeline with DICE’s specialized treatments and reflecting Eli Lilly's commitment to advancing immunological therapies. Cleveland Clinic & Medtronic 🏥💓 Details: Cleveland Clinic, a leading healthcare provider based in the U.S., and Medtronic, a global medical technology company headquartered in Ireland, are expanding their strategic partnership. Medtronic’s acquisition of additional shares in Cleveland Clinic’s spin-off companies will drive forward innovations in cardiovascular care. This partnership integrates Medtronic’s advanced medical technologies with Cleveland Clinic’s clinical expertise, aiming to improve patient outcomes in cardiovascular medicine. Pfizer & Global Blood Therapeutics 💊🩸 Details: Pfizer, a major pharmaceutical company headquartered in the U.S., has completed its acquisition of Global Blood Therapeutics, also based in the U.S., for $5.4 billion. Global Blood Therapeutics is known for its treatments for sickle cell disease and other rare blood disorders. This acquisition reinforces Pfizer’s position in the hematology field and aligns with its strategy to address complex and rare medical conditions through innovative therapies. Abbott Laboratories & Scripps Research 🔬🔍 Details: Abbott Laboratories, an American multinational healthcare company, has acquired certain assets from Scripps Research, a renowned biomedical research institute based in the U.S. This acquisition aims to advance Abbott’s capabilities in diagnostics and personalized medicine. By integrating Scripps Research’s cutting-edge technologies and research assets, Abbott is positioned to enhance its diagnostic tools and develop personalized treatment solutions, reflecting its commitment to innovation in medical diagnostics and precision medicine.